BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 28974115)

  • 1. Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.
    Presland RB
    Expert Rev Proteomics; 2017 Nov; 14(11):997-1006. PubMed ID: 28974115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines.
    Budde H; Papert S; Maas JH; Reichardt HM; Wulf G; Hasenkamp J; Riggert J; Legler TJ
    Ann Hematol; 2017 Jul; 96(7):1127-1133. PubMed ID: 28447161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants.
    Iacobescu M; Pop C; Uifălean A; Mogoşan C; Cenariu D; Zdrenghea M; Tănase A; Bergthorsson JT; Greiff V; Cenariu M; Iuga CA; Tomuleasa C; Tătaru D
    Front Immunol; 2024; 15():1327035. PubMed ID: 38433830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and validation of graft-versus-host disease biomarkers.
    Paczesny S
    Blood; 2013 Jan; 121(4):585-94. PubMed ID: 23165480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.
    Dander E; De Lorenzo P; Bottazzi B; Quarello P; Vinci P; Balduzzi A; Masciocchi F; Bonanomi S; Cappuzzello C; Prunotto G; Pavan F; Pasqualini F; Sironi M; Cuccovillo I; Leone R; Salvatori G; Parma M; Terruzzi E; Pagni F; Locatelli F; Mantovani A; Fagioli F; Biondi A; Garlanda C; Valsecchi MG; Rovelli A; D'Amico G
    Oncotarget; 2016 Dec; 7(50):82123-82138. PubMed ID: 27893415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma biomarkers in graft-versus-host disease: a new era?
    Paczesny S; Levine JE; Braun TM; Ferrara JL
    Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):33-8. PubMed ID: 19147075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Could mucin 16 and colony-stimulating factor 2-receptor beta possible graft versus host disease biomarkers? Medical hypotheses.
    Souza MM; de Paula FM; Hsieh R; Macedo MC; Corral MA; Nunes TB; De Paula F; Lourenço SV
    Med Hypotheses; 2017 Mar; 100():89-93. PubMed ID: 28236856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fecal but not serum calprotectin is a potential marker of GVHD after stem cell transplantation.
    Metafuni E; Giammarco S; De Ritis DG; Rossi M; De Michele T; Zuppi C; Bacigalupo AP; Sica S; Chiusolo P
    Ann Hematol; 2017 Jun; 96(6):929-933. PubMed ID: 28293713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for acute and chronic graft versus host disease: state of the art.
    Giaccone L; Faraci DG; Butera S; Lia G; Di Vito C; Gabrielli G; Cerrano M; Mariotti J; Dellacasa C; Felicetti F; Brignardello E; Mavilio D; Bruno B
    Expert Rev Hematol; 2021 Jan; 14(1):79-96. PubMed ID: 33297779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Proteomics for Post-Hematopoeitic Stem Cell Transplantation Outcomes.
    Paczesny S; Metzger J
    Proteomics Clin Appl; 2019 Mar; 13(2):e1800145. PubMed ID: 30307119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.
    Paczesny S; Hakim FT; Pidala J; Cooke KR; Lathrop J; Griffith LM; Hansen J; Jagasia M; Miklos D; Pavletic S; Parkman R; Russek-Cohen E; Flowers ME; Lee S; Martin P; Vogelsang G; Walton M; Schultz KR
    Biol Blood Marrow Transplant; 2015 May; 21(5):780-92. PubMed ID: 25644957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.
    Ali AM; DiPersio JF; Schroeder MA
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1552-1564. PubMed ID: 27158050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salivary proteomic analysis and acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Chiusolo P; Giammarco S; Fanali C; Bellesi S; Metafuni E; Sica S; Iavarone F; Cabras T; Messana I; Leone G; Castagnola M
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):888-92. PubMed ID: 23529013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for acute GVHD: can we predict the unpredictable?
    Chen YB; Cutler CS
    Bone Marrow Transplant; 2013 Jun; 48(6):755-60. PubMed ID: 22863728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis.
    Srinivasan R; Daniels J; Fusaro V; Lundqvist A; Killian JK; Geho D; Quezado M; Kleiner D; Rucker S; Espina V; Whiteley G; Liotta L; Petricoin E; Pittaluga S; Hitt B; Barrett AJ; Rosenblatt K; Childs RW
    Exp Hematol; 2006 Jun; 34(6):796-801. PubMed ID: 16728285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tear Film Proteomics Reveal Important Differences Between Patients With and Without Ocular GvHD After Allogeneic Hematopoietic Cell Transplantation.
    Gerber-Hollbach N; Plattner K; O'Leary OE; Jenoe P; Moes S; Drexler B; Schoetzau A; Halter JP; Goldblum D
    Invest Ophthalmol Vis Sci; 2018 Jul; 59(8):3521-3530. PubMed ID: 30025099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
    Lee KH; Choi SJ; Lee JH; Lee JS; Kim WK; Lee KB; Sohn SK; Kim JG; Kim DH; Seol M; Lee YS; Lee JH
    Haematologica; 2005 Jul; 90(7):939-48. PubMed ID: 15996932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.
    Ferrara JL; Harris AC; Greenson JK; Braun TM; Holler E; Teshima T; Levine JE; Choi SW; Huber E; Landfried K; Akashi K; Vander Lugt M; Reddy P; Chin A; Zhang Q; Hanash S; Paczesny S
    Blood; 2011 Dec; 118(25):6702-8. PubMed ID: 21979939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.
    Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB
    Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.